Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 2:49 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 62 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Dimethyl fumarate Clear all
Completed No phase listed Observational

Biogen Multiple Sclerosis Pregnancy Exposure Registry

NCT01911767
View directory record Official record
Conditions
Multiple Sclerosis, Exposure During Pregnancy
Interventions
Dimethyl fumarate, Peginterferon beta-1a
Drug
Lead sponsor
Biogen
Industry
Eligibility
Female only
Enrollment
408 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2022
U.S. locations
1
States / cities
Cambridge, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 21, 2022 · Synced Oct 17, 2026, 2:49 PM EDT
Completed No phase listed Observational

Dimethyl Fumarate (DMF) Observational Study

NCT02047097
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
dimethyl fumarate
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years and older
Enrollment
5,487 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2022
U.S. locations
168
States / cities
Birmingham, Alabama • Huntsville, Alabama • Gilbert, Arizona + 140 more
Source: ClinicalTrials.gov public record
Updated May 24, 2023 · Synced Oct 17, 2026, 2:49 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety Study of Oral BG00012 With Active Reference in Relapsing-Remitting Multiple Sclerosis

NCT00451451
View directory record Official record
Conditions
Relapsing-Remitting Multiple Sclerosis
Interventions
BG00012, Placebo, Glatiramer Acetate
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 55 Years
Enrollment
1,417 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
72
States / cities
Birmingham, Alabama • Cullman, Alabama • Huntsville, Alabama + 69 more
Source: ClinicalTrials.gov public record
Updated Jan 26, 2015 · Synced Oct 17, 2026, 2:49 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Effect of Aspirin Pretreatment or Slow Dose Titration on Flushing and Gastrointestinal Events in Healthy Volunteers Receiving Delayed-release Dimethyl Fumarate

NCT01568112
View directory record Official record
Conditions
Healthy
Interventions
BG00012 (dimethyl fumarate), BG00012 placebo, ASA, ASA placebo
Drug
Lead sponsor
Biogen
Industry
Eligibility
25 Years to 55 Years
Enrollment
173 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 13, 2016 · Synced Oct 17, 2026, 2:49 PM EDT
Completed No phase listed Observational

Adherence to Treatment With Tecfidera™ in Multiple Sclerosis Patients

NCT02099370
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Not listed
Lead sponsor
University of South Florida
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Apr 3, 2020 · Synced Oct 17, 2026, 2:49 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study in Healthy Volunteers to Establish the BioEquivalence of Two Formulations of BG00012

NCT01420458
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Experimental
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 55 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 4, 2011 · Synced Oct 17, 2026, 2:49 PM EDT
Completed Phase 3 Interventional Results available

Phase 3 Efficacy and Safety Study of BG00012 in Pediatric Participants With Relapsing-Remitting Multiple Sclerosis (RRMS)

NCT02283853
View directory record Official record
Conditions
Relapsing-Remitting Multiple Sclerosis
Interventions
dimethyl fumarate, Interferon β-1a
Drug
Lead sponsor
Biogen
Industry
Eligibility
10 Years to 17 Years
Enrollment
156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2025
U.S. locations
2
States / cities
Boston, Massachusetts • Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated May 19, 2026 · Synced Oct 17, 2026, 2:49 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Compare GI Tolerability Following Oral Administration of Bafiertam™ or Tecfidera to Healthy Volunteers

NCT04022473
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Bafiertam, Tecfidera
Drug
Lead sponsor
Banner Life Sciences LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
210 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated Jan 18, 2020 · Synced Oct 17, 2026, 2:49 PM EDT
Completed Phase 2 Interventional Results available

Dimethyl Fumarate for Obstructive Sleep Apnea

NCT02438137
View directory record Official record
Conditions
Obstructive Sleep Apnea, OSA, Sleep Apnea
Interventions
Dimethyl fumarate, Placebo
Drug
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 65 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated May 31, 2017 · Synced Oct 17, 2026, 2:49 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Oral BG00012 in Relapsing-Remitting Multiple Sclerosis

NCT00420212
View directory record Official record
Conditions
Relapsing-Remitting Multiple Sclerosis
Interventions
BG00012, Placebo
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 55 Years
Enrollment
1,234 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
39
States / cities
Gilbert, Arizona • Phoenix, Arizona • San Francisco, California + 36 more
Source: ClinicalTrials.gov public record
Updated Jan 26, 2015 · Synced Oct 17, 2026, 2:49 PM EDT
Completed Phase 2 Interventional Results available

Study of the Effect of BG00012 on MRI Lesions and Pharmacokinetics in Pediatric Subjects With RRMS

NCT02410200
View directory record Official record
Conditions
Multiple Sclerosis, Relapsing-Remitting
Interventions
dimethyl fumarate
Drug
Lead sponsor
Biogen
Industry
Eligibility
10 Years to 17 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
San Bernardino, California
Source: ClinicalTrials.gov public record
Updated Oct 23, 2017 · Synced Oct 17, 2026, 2:49 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of ALKS 8700, a Monomethyl Fumarate (MMF) Molecule, in Healthy Adults

NCT02201849
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Study Drug, Active Control, Placebo
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 55 Years
Enrollment
104 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Nov 26, 2019 · Synced Oct 17, 2026, 2:49 PM EDT
Terminated Phase 3 Interventional Results available

Clinical Study to Compare the Efficacy and Safety of Ponesimod to Placebo in Subjects With Active Relapsing Multiple Sclerosis Who Are Treated With Dimethyl Fumarate (Tecfidera®)

NCT02907177
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Ponesimod, Placebo
Drug · Other
Lead sponsor
Actelion
Industry
Eligibility
18 Years to 55 Years
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
26
States / cities
Birmingham, Alabama • Fresno, California • Pasadena, California + 22 more
Source: ClinicalTrials.gov public record
Updated May 18, 2021 · Synced Oct 17, 2026, 2:49 PM EDT
Completed Phase 3 Interventional Results available

Extension Study of BG00012 in Pediatric Subjects With Relapsing Remitting Multiple Sclerosis (RRMS)

NCT02555215
View directory record Official record
Conditions
Multiple Sclerosis, Relapsing-Remitting
Interventions
dimethyl fumarate
Drug
Lead sponsor
Biogen
Industry
Eligibility
10 Years to 17 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Loma Linda, California
Source: ClinicalTrials.gov public record
Updated Nov 22, 2019 · Synced Oct 17, 2026, 2:49 PM EDT
Terminated Phase 4 Interventional Results available

RESOunD: REbif Satisfaction On Discontinuing Oral Dimethyl Fumarate

NCT02117050
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Rebif®
Drug
Lead sponsor
EMD Serono
Industry
Eligibility
18 Years to 65 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 23, 2017 · Synced Oct 17, 2026, 2:49 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Healthy Volunteer Study to Establish the Bioequivalence of BG00012 Supplied by 2 Different Commercial Manufacturers

NCT02171208
View directory record Official record
Conditions
Healthy
Interventions
dimethyl fumarate - Reference form, dimethyl fumarate - Test form
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 55 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
2
States / cities
Daytona Beach, Florida • Evansville, Indiana
Source: ClinicalTrials.gov public record
Updated Jan 9, 2015 · Synced Oct 17, 2026, 2:49 PM EDT
Withdrawn No phase listed Observational

Comparison of Rebif Compared to Tecifdera on Six-month Outcomes in Patients With Relapsing-remitting MS

NCT02419638
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Rebif (IFN β-1a subcutaneous three times per week), Tecifdera (dimethyl fumarate)
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Brookline, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 29, 2016 · Synced Oct 17, 2026, 2:49 PM EDT
Completed Phase 3 Interventional Results available

BG00012 Monotherapy Safety and Efficacy Extension Study in Multiple Sclerosis (MS)

NCT00835770
View directory record Official record
Conditions
Relapsing-Remitting Multiple Sclerosis
Interventions
dimethyl fumarate, Placebo
Drug
Lead sponsor
Biogen
Industry
Eligibility
19 Years to 58 Years
Enrollment
1,736 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2019
U.S. locations
50
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mesa, Arizona + 44 more
Source: ClinicalTrials.gov public record
Updated Dec 31, 2020 · Synced Oct 17, 2026, 2:49 PM EDT
Terminated Phase 3 Interventional Results available

BG00012 and Delay of Disability Progression in Secondary Progressive Multiple Sclerosis

NCT02430532
View directory record Official record
Conditions
Multiple Sclerosis, Secondary Progressive
Interventions
dimethyl fumarate, Placebo
Drug · Other
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 58 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
7
States / cities
Long Beach, California • San Francisco, California • Tampa, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 26, 2017 · Synced Oct 17, 2026, 2:49 PM EDT
Completed Phase 2 Interventional Results available

BG00012 Phase 2 Combination Study in Participants With Multiple Sclerosis

NCT01156311
View directory record Official record
Conditions
Relapsing-Remitting Multiple Sclerosis, Multiple Sclerosis
Interventions
dimethyl fumarate
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 55 Years
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
16
States / cities
Gilbert, Arizona • Phoenix, Arizona • Danbury, Connecticut + 13 more
Source: ClinicalTrials.gov public record
Updated Mar 21, 2017 · Synced Oct 17, 2026, 2:49 PM EDT
Terminated No phase listed Observational

Restoring Glutathione Synthesis With Tecfidera: An in Vivo H-MRS Single-Arm Study at 7T in Patients With RR MS

NCT02218879
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Tecfidera
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 60 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Sep 5, 2016 · Synced Oct 17, 2026, 2:49 PM EDT
Completed No phase listed Observational

Pilot Study to Assess Disease Stability in a Natalizumab to Dimethyl Fumarate Crossover Design

NCT01945359
View directory record Official record
Conditions
Relapsing Remitting Multiple Sclerosis
Interventions
Not listed
Lead sponsor
Rocky Mountain MS Research Group, LLC
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Oct 16, 2015 · Synced Oct 17, 2026, 2:49 PM EDT
Completed No phase listed Observational

Observational Study to Characterize Real-world Clinical Outcomes With Relapsing-remitting Multiple Sclerosis (RRMS)

NCT02776072
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Not listed
Lead sponsor
Biogen
Industry
Eligibility
18 Years and older
Enrollment
2,978 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
38
States / cities
Homewood, Alabama • Gilbert, Arizona • Hanford, California + 33 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2017 · Synced Oct 17, 2026, 2:49 PM EDT
Terminated No phase listed Observational

Tecfidera and MRI for Brain Energy in MS

NCT02644083
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Dimethyl fumarate
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years to 55 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Aug 29, 2018 · Synced Oct 17, 2026, 2:49 PM EDT